SLC5A2 and type 2 diabetes mellitus: Since this study was conducted before use of SGLT2 inhibitors became standard practice in type 2 diabetes care (which, to date, is the only effective therapy with proven glucose-lowering and cardiovascular-protective effects [15, 16]) screening is likely to be even more beneficial in the present day.